Berkeley, CA and Vancouver, BC – September 15, 2016 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF) is pleased to announce that it has entered into an agreement (the “Agreement”) with RK Equity Advisors LLC and TrueNorth Lifesciences LLC (“RK TrueNorth”) for the provision of corporate advisory services. The Agreement is …
BERKELEY, CALIFORNIA and VANCOUVER, BRITISH COLUMBIA–(Marketwired – Aug. 19, 2016) – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX VENTURE:BCT)(OTCQB:BCTXF) is pleased to announce it has completed its previously announced non-brokered private placement financing (the “Offering”) of units (the “Units”) for aggregate gross proceeds to the Company in the amount of $1,700,000. Under the Offering, …
– Dr. Jarrod P. Holmes, a prominent breast cancer vaccine expert to lead the study out of St. Joseph Health-Sonoma County Berkeley, CA and Vancouver, BC – August 17, 2016 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF) is pleased to announce that Dr. Jarrod P. Holmes, a Board Certified Oncologist …
BriaCell Therapeutics Corp. (OTCQB:BCTXF)(TSX VENTURE:BCT) (“BriaCell”, the “Company”, or “BCT”) announced today that it intends to complete a non-brokered private placement (the “Offering”) of units of the Company (the “Units”) at a price of $0.20 per Unit for aggregate gross proceeds of up to $1,500,000. Under the Offering, each Unit shall consist of one common …
BERKELEY, CA and VANCOUVER, BC–(Marketwired – May 18, 2016) – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX VENTURE: BCT) (OTCQB: BCTXF) is pleased to announce that it has signed a definitive agreement with Cancer Insight, LLC, a cancer-vaccine focused clinical research organization (CRO), to initiate Phase I/IIa clinical studies and regulatory filings for BriaVax™, …
Berkeley, CA and Vancouver, BC – Tuesday May 10, 2016 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF) today announced a change to its board of directors. BriaCell is pleased to welcome the appointment of Mr. Martin Schmieg to its Board of Directors. Mr. Schmieg, with 35 years of business experience, …
Berkeley, CA and Vancouver, BC – May 3, 2016 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF) is pleased to announce that the Company has completed both its previously announced brokered and non-brokered private placements of units totaling gross proceeds of C$1,275,000. BriaCell intends to use the proceeds from the financings …
BriaCell Therapeutics Corp. (TSX VENTURE:BCT)(OTCQB:BCTXF) (“BriaCell”, the “Company”, or “BCT”) announced today that it intends to complete a non-brokered private placement (the “Offering”) of units of the Company (the “Units”) at a price of $0.20 per Unit for aggregate gross proceeds of up to C$600,000. The Offering is in addition to the Company’s proposed strategic …
Berkeley, CA and Vancouver, BC – April 22, 2016 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF) is very pleased to announce that it has entered into an agreement with a leading US biotechnology fund for an investment of C$650,000. The subscription agreement of units (“Units”) is priced at C$0.19, each …
– Data Presentation at American Association for Cancer Research (AACR) Annual Meeting 2016 – Berkeley, CA and Vancouver, BC – April 12, 2016 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF) is very pleased to announce that it has filed a provisional patent application with the U.S. Patent and Trademark Office …